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chemoselective peptide cyclization and
functionalization†‡
Marc-Andre´ Kasper,§ab Maria Glanz,§ab Andreas Oder,a Peter Schmieder,a Jens P. von
Kriesa and Christian P. R. Hackenberger *ab
In this paper, we introduce vinylphosphonites for chemoselective Staudinger-phosphonite reactions (SPhR)
with azides to form vinylphosphonamidates for the subsequent modification of cysteine residues
in peptides and proteins. An electron-rich alkene is turned into an electron-deficient
vinylphosphonamidate, thereby inducing electrophilic reactivity for a following thiol addition. We show
that by varying the phosphonamidate ester substituent we can fine-tune the reactivity of the thiol
addition and even control the functional properties of the final conjugate. Furthermore, we observed
a drastic increase in thiol addition efficiency when the SPhR is carried out in the presence of a thiol
substrate in a one-pot reaction. Hence, we utilize vinylphosphonites for the chemoselective
intramolecular cyclization of peptides carrying an azide-containing amino acid and a cysteine in high
yields. Our concept was demonstrated for the stapling of a cell-permeable peptidic inhibitor for protein–
protein interaction (PPI) between BCL9 and beta-catenin, which is known to create a transcription factor
complex playing a role in embryonic development and cancer origin, and for macrocyclization of cell-
penetrating peptides (CPPs) to enhance the cellular uptake of proteins.Introduction
Selective chemical modication of the sulydryl group of
cysteine is an important tool in the life sciences.1,2 Cysteine-
selective reactions have been employed to covalently modify
proteins in a residue specic manner for various applications
including drug delivery,3 incorporation of post-translational
modications4 and activity based protein proling.5
A plethora of different techniques have been developed in
the past few decades that allow for selective modication of
cysteine residues on peptides and proteins based on various
reaction mechanisms. Michael additions to a,b-unsaturated
carbonyl compounds in maleimides,6 sulfone reagents7 and
recently developed carbonylacrylic reagents8 are the most
prominent examples. Other methods rely on SN2-reactions of
haloalkyl bonds such as iodoacetamides,9 on alkynylation10 and
uoroalkylation11 with hypervalent iodine reagents, onPharmakologie (FMP), Chemical Biology
25 Berlin, Germany. E-mail: hackenbe@
t of Chemistry, Brook-Taylor-Str. 2, 12489
es on the occasion of his 60th birthday.
tion (ESI) available. See DOI:
9nucleophilic aromatic substitution of peruoroaromatic
compounds12 or on Pd-mediated cross-coupling.13 The level of
reactivity for cysteine in these methods is predetermined by the
chemical nature of the reactive group itself. Alteration of this
reactivity is oen difficult and requires tedious chemical
manipulations. However, certain applications such as activity
based protein proling14 or covalent enzyme inhibition15 oen
rely on reduced reactivity that allows for modication of the
active site cysteine while sparing all other free nucleophiles in
the proteome. Such decreased reactivity has for instance been
achieved by substituting the highly reactive iodide in a-hal-
oacetamides with a less reactive chloride.16 Therefore, a cysteine
selective modication method that utilizes easily tunable elec-
trophilic warheads would be highly attractive for addressing
challenges in peptide and protein chemistry.
Aside from protein modication, cysteine selective reac-
tions have also been applied to peptide synthesis. One or two
covalent linkages between cysteine residues in peptides enable
the construction of macro or bicyclized peptides with
enhanced biophysical and pharmacological properties.17 Upon
macrocyclization, peptidic structures can become more stable
against proteases,18 they can be locked in their structural
conformation by covalently linking side chains and therefore
restricting their conformational exibility19,20 or increasing
their function by rigid constraint as shown for various cyclic
bioactive21 or cell penetrating peptides (cCPPs).22 The groups
of Pentelute and Derda introduced peruoroaromatic linkagesThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinefor the cyclization of peptides containing two cysteines.23,24
Tricyclic peptides have also been synthesized by alkylation
with tris-(bromomethyl)benzene25 and very recently by the
incorporation of two chemical bridges with a set of various
dibromoalkyl reagents.26 Such chemoselective modication
strategies are advantageous over common cyclization tech-
niques27 such as lactamization,28 since they can be applied
aer cleavage from the resin and preclude therefore tedious
orthogonal protecting group strategies during SPPS. In addi-
tion, even cysteine containing proteins can be cyclized by
applying chemoselective techniques, as recently demonstrated
with the aid of a trimeric chloroacetamide.29
Based on the Staudinger-phosphonite reaction (SPhR),
developed in our laboratory,30 we recently introduced ethynyl-
phosphonamidates as cysteine-selective electrophiles that can
be chemoselectively incorporated starting from ethynylphos-
phonites.31 In the current paper, we report vinylphosphonites as
a new compound class for the transformation of azides into
electron decient alkenes that selectively modify cysteine resi-
dues in peptides and proteins. We observed that the SPhR with
vinylphosphonites facilitates straightforward access to vinyl-
phosphonamidates carrying different O-substituents. We
discovered that the rate of the subsequent thiol addition can be
drastically inuenced by the electronic properties of these
phosphonamidate ester substituents. In addition, we engi-
neered an intramolecular variant of the chemically induced
thiol addition for a chemoselective cyclization of peptides. We
were able to demonstrate that azido modied cysteine peptides
can be cyclized upon SPhR with vinylphosphonites in high
yields (Scheme 1). In contrast to other chemoselective peptide
cyclizations, which have been mainly used for head-to-tail
cyclizations, including traceless Staudinger ligation,32 a-ketoa-
cid–hydroxylamine amide-ligation33 or serine ligation,34 the
method presented herein can be straightforwardly applied to
side-chain ring closure.
Results and discussion
Previously, Gao et al. have observed that methyl-substituted
vinylphosphonamidates are unreactive in base mediated thiol
additions,35 probably due to decreased electrophilicity,
compared to their ethynyl substituted counterparts.31 We
anticipated that the electrophilic reactivity of the double bond
towards thiol-addition can be increased by attaching different
electron-withdrawing substituents to the phosphonamidate
ester moiety. Since this residue is preserved during SPhR with
azides, we started our investigations by synthesizing differentScheme 1 Vinylphosphonites for intramolecular peptide cyclization and
This journal is © The Royal Society of Chemistry 2019substituted vinylphosphonites. Here, we followed previously
published procedures starting from either phosphorus tri-
chloride (route I) or bis(diisopropylamino)-chlorophosphine
(route II).36 Several attempts to isolate unprotected vinyl-
phosphonites failed due to product decomposition, hence we
decided to isolate the phosphonites in their borane-protected
form and use them directly as starting materials for the
subsequent SPhR. Vinylphosphonite borane adducts proved to
be stable during column chromatography and we were able to
obtain four vinylphosphonites with ethyl, 1a, phenyl, 1b and
electron withdrawing 2-nitrobenzyl, 1c, and triuoroethyl, 1d,
substituents (Fig. 1a).
With vinylphosphonites 1a–d in hand, we continued our
studies to perform the SPhR with two different model azides 2
and 3 to synthesize both N-phenyl 4a–d and N-alkyl substituted
vinylphosphonamidates 5a–d. Here, we applied previously
published procedures, either diethyl chlorophosphite alkyl-
ation with vinylmagnesium bromide31 (route III) or borane
deprotection with DABCO in toluene37 (route IV), directly fol-
lowed by azide addition and hydrolysis without isolation of the
phosphonite intermediate. The SPhR was always carried out in
dry solvents to prevent hydrolysis of the phosphonites. All of the
tested phosphonites reacted smoothly under the tested condi-
tions and the desired vinylphosphonamidates could be isolated
by column chromatography. Electron withdrawing substituents
were well tolerated in the reaction with the aryl azide 2 and with
the alkyl azide 3 (Fig. 1b).
Next, we probed the reactivity of the synthesized vinyl-
phosphonamidates towards thiol addition in aqueous solution
under slightly basic conditions as previously performed for
ethynylphosphonamidates31 (Fig. 2a). For this, a time course for
the addition of glutathione (GSH) to vinylphosphonamidates
4a–d and 5a–d in ammonium bicarbonate buffer was recorded.
Under the tested conditions (10 mM phosphonamidate and
two equivalents of GSH) the N-phenyl vinylphosphonamidate 4a
showed a good conversion of 80% to the desired thiol adduct
aer 24 h. In contrast to 4a, the comparable N-alkyl derivative 5a
was only converted 20% under the same conditions (Fig. 2b),
which is in accordance with the observations of Gao et al. on the
unreactivity of N-alkyl-O-methyl-vinylphosphonamidate
towards thiols; however, the previously mentioned deal-
kylation of the phosphonamidate ester was not observed under
conditions applied here. Since we assumed that such slow
kinetics would limit the applicability to protein modication,
for example by undesired disulde formation of the peptide or
protein substrate, we also tested compounds with electron-cysteine selective protein modification.
Chem. Sci., 2019, 10, 6322–6329 | 6323
Fig. 1 (a) Synthesis of substituted vinylphosphonites from phosphorus
trichloride (route I) or bis(diisopropylamino)chlorophosphine (route II).
Stated are isolated yields. (b) One-pot SPhR with vinylphosphonites
and azides. Synthesis from borane protected vinylphosphonites (route
III) or diethyl chlorophosphite (route IV). Stated are isolated yields.
Fig. 2 (a) Reaction of glutathione (GSH) with differently substituted
vinylphosphonamidates. 10 mM vinylphosphonamidates were reacted
with 20 mM GSH at pH 8.5 (NH4HCO3 buffer). Concentration of the
starting materials over time, mean and error from three independent
measurements, monitored by UPLC-UV. (b) N-Phenyl vs. N-alkyl
comparison. (c) Comparison of different O-substituents. Dotted line
depicts 50% conversion.
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View Article Onlinedecient phosphonamidate ester substituents in the addition of
glutathione. A conversion of 50% is reached aer two and a half
hours for 2-nitrobenzyl compound 4b and aer only 30 minutes
for triuoroethyl substituted 4d. The O-phenyl compound 4c
shows an accelerating effect over alkoxy-substituents as well,
reaching 50% conversion in only one hour (Fig. 2c). These6324 | Chem. Sci., 2019, 10, 6322–6329results clearly show that the reactivity of vinyl-
phosphonamidates can be tuned by varying the phosphona-
midate ester residue. The corresponding N-alkyl substituted
compounds 5a–d also undergo rate enhancement with more
electron withdrawing O-substituents, with a slower reaction
compared to the N-phenyl substituted compounds 4a–d in
general (ESI Fig. S1‡). Notably, the glutathione adduct was the
only detectable product by UPLC/MS and no other side product
was observed for any of the tested phosphonamidates (ESI
Fig. S2‡). The identity of the thiol-glutathione adducts of 4a (ESI
Fig. S3‡) and 4d was conrmed by NMR characterization aer
isolation by preparative HPLC in 60% and 89% yield,
respectively.
Further kinetic investigations of the thiol addition to 4d,
being the fastest compound tested in this study (ESI Fig. S1‡),
revealed a second-order rate constant of 0.021 M1 s1 (ESI
Fig. S4‡). Even though this is considerably slower than that of
maleimides (734 M1 s1),38 ethynylphosphonamidates (0.62
M1 s1)31 and recently introduced dinitroimidazoles,39 the rate
is still higher or in the range of other protein modicationThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinereactions such as oxime, Staudinger or Pictet–Spengler liga-
tions.38 Next to reaction rates, an important aspect for many
applications of cysteine selective protein modication reagents
is susceptibility of the conjugate towards thiol exchange.1 Mal-
eimides are in particular known to undergo retro Michael
addition, followed by transfer of the modication to other
cysteine containing molecules in solution.40 To prove the
stability of the vinylphosphonamidate adducts in the presence
of other thiols, we incubated the glutathione adducts of 4a and
4d with an excess of 100 equivalents of 2-mercaptoethanesul-
fonate. Even aer one week of incubation, no thiol exchange
could be observed for both of the constructs by UPLC/MS (ESI
Fig. S5‡).
Next, we wanted to probe the reactivity of electron-poor
vinylphosphonamidates towards cysteine modication on
antibodies. For this, we synthesized a uorescent EDANS-
modied vinylphosphonamidate 6, analogously to compound
4d, with the N-phenyl-O-triuoroethyl substitution pattern that
has been identied to be superior in thiol addition kinetics.
Based on a previously established protocol31 we reduced the
four interchain disulde bonds of cetuximab to generate 8 free
cysteine residues and probed the reactivity towards 6 (Fig. 3a).
Successful labelling aer reduction and incubation with 20
equivalents of reagent per antibody was conrmed by in-gel
uorescence (Fig. 3b). Intact protein MS revealed a decentFig. 3 Cetuximab modification with 6. (a) Reduction and alkylation
principles and structure of 6. (b) Gel analysis: reactions were carried
out with varying equivalents of 6: Lane 1: untreated antibody. Lane 2–
4: control reactions without prior DTT treatment. Lane 5–7: prior DTT
treatment. HC: antibodies' heavy chain, LC: light chain.
This journal is © The Royal Society of Chemistry 2019degree of modication of 3.8 uorophore molecules per anti-
body (ESI Fig. S6‡). To probe the cysteine selectivity, a control
experiment without prior antibody reduction was performed
and no modication could be detected aer incubation with 20
equivalents of 6 by in-gel uorescence and MS. Only upon
exposure of the unreduced antibody to high reagent excesses of
more than 50 equivalents per antibody, low degrees of modi-
cation were observed (Fig. 3b). The observation of unspecic
labelling at higher reagent concentrations was further investi-
gated by mass spectrometry (LC-MS/MS) aer trypsin digestion
of the reduced antibody modied with 100 eq. of 4d (ESI
Fig. S7‡). In addition to the inter-chain disulde forming
cysteines, a few lysine residues were also found to be modied.
This cross-reactivity with lysine is also known for other cysteine
labelling reagents such as iodoacetamides41 and maleimides.42
The ndings are nevertheless contrary to our previously re-
ported ethynylphosphonamidate reagents that exhibit excellent
cysteine selectivity even with large reagent excesses.31 To further
broaden the scope of our method, we also synthesized a biotin-
modied 2-nitrobenzyl-phosphonamidate with a structure that
has the same substitution pattern as compound 4b. Successful
antibody labelling was conrmed by anti-biotin Western blot
analysis. Analogously to the triuoroethyl compound, only
prolonged reaction times lead to minor labelling degrees
without prior reduction of the antibody disulde bonds (ESI
Fig. S8‡). Taken together, we were able to show that vinyl-
phosphonamidates can lead to efficient and selective modi-
cation of cysteine residues on proteins using only slight reagent
excesses.
We further anticipated that the SPhR with subsequent thiol
addition could also be applied in an intramolecular reaction.
Therefore we synthesized an azidohomoalanine- and cysteine-
containing peptide, aiming to initiate a covalent cyclization.
As the rst proof of principle study, we chose to macrocyclize
the BCL9 derived peptide 8a, which has been reported to act as
a potent PPI-inhibitor when stapled by ring closing metathesis
(RCM).43 We decided to replace the two olenic amino acids in
the i,i+4 position with azidohomoalanine and cysteine in order
to keep the linker length (10 atoms) similar to that of the
literature-known peptide 7 (Scheme 2). In our initial experi-
ments we aimed to keep a double bond in the linker structure
for more rigidity and hence used an ethyl-substituted ethynyl-
phosphonite in the reaction with peptide 8a in dry DMSO based
on our previously published conditions.31 However, we found
that in order to promote the initial SPhR with the alkylazide of
azidohomoalanine the reaction temperature had to be raised to
50 C, upon which the macrocyclized product formed only in
low amounts. A major side product observed by UPLC-UV/MS
was a peptide with an additional 28 Da, which we attribute to
the alkylation of the nitrogen of the phosphonamidate. Similar
N-alkylated phosphoramidates were reported previously by us
aer the rearrangement of phosphorimidates under elevated
temperatures.44 We hypothesized that raising the reactivity of
the phosphonite by using a more nucleophilic vinyl- as opposed
to the ethynyl-phosphonite in the SPhR enables the use of lower
reaction temperature and would thereby prevent the rear-
rangement to the alkylated byproduct. Therefore puriedChem. Sci., 2019, 10, 6322–6329 | 6325
Scheme 2 Principle of the intramolecular peptide cyclization of an
azido containing cysteine-BCL-9 derived peptide. Investigations with
a capped cysteine peptide (9) revealed an accelerated thiol addition
when SPhR is performed in the presence of thiols. SPhR on peptides is
always carried out with the crude diethyl phosphonite, synthesized
from diethyl chlorophosphite (route III).
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View Article Onlinepeptide 8a was reacted with crude diethyl vinylphosphonite
(route III) aer SPPS in an over-night reaction in DMSO. To our
delight, we isolated the desired cyclized peptide 9a aer
preparative HPLC as the main product in a very good yield of
45%. This result is particularly remarkable in light of the slow
intermolecular thiol addition to O-ethyl-N-alkyl-
vinylphosphonamidates such as 5a as shown before (Fig. 2b).
UPLC/MS showed a clean conversion towards the desired
product without signicant amounts of the side product (ESI
Fig. S9‡).
To gain more insight into the in situ intramolecular cycliza-
tion, we capped the cysteine of peptide 8a with iodoacetamide
to form peptide 10. This peptide was reacted with glutathione
under two different reaction conditions (Scheme 2). First,
glutathione was added in a one-pot reaction with peptide 10
(1.65 mM) and 5 eq. diethyl vinylphosphonite. Here, the thiol
addition product 12 could be observed by LC-MS as the major
product (ESI Fig. S10‡). In the second experiment, we reacted
peptide 10 with 5 eq. vinyl phosphonite to form the phospho-
namidate 11 aer hydrolysis, as observed by LC-MS. Aer
lyophilization peptide 11 was incubated with 1 eq. glutathione6326 | Chem. Sci., 2019, 10, 6322–6329(1.65 mM) in DMSO for 24 hours. Under these conditions, no
product formation could be observed by MS analysis (ESI
Fig. S10‡). This experiment again points towards the decreased
reactivity of ethyl-substituted vinylphosphonamidates in inter-
molecular reactions with thiol substrates (see Fig. 2a and ref.
35), and furthermore implies that the in situ process benets
from the reaction of thiols with a more reactive SPhR
intermediate.
With the phosphonamidate-cyclized BCL9 peptide 9a in
hand we set out to investigate its stability and helicity. At rst,
9a was incubated at different pH values over several days and
the stability monitored by UPLC. Under acidic conditions
below pH 2 the P–N-bond gets cleaved within 24 hours, which
is in accordance with our previous observations.31 At neutral
and basic pH, the phosphonamidate moiety proved to be
stable over several days without any observable decomposition
(Fig. 4a and b). Next, we evaluated the peptides' helical
propensities by CD spectroscopy and could show a drastic
increase in helicity upon cyclization from 20% to around 50%
(Fig. 4d). To verify the ability to disrupt the PPI between
puried BCL9 and b-catenin we used a homogeneous assay
with time resolved uorescence (HTRF), in which both inter-
acting proteins were recognized by distinct antibodies via
orthogonal tags and conjugated uorophores suitable for
energy transfer.45 Disturbance of the protein–protein interac-
tion causes a decreased FRET signal (ESI Fig. S11‡). Using this
assay, we could show that the phosphonamidate cyclized
peptides can disrupt the PPI at concentrations in the nM range
(Fig. 4e). The IC50 values are almost identical to those reported
for the RCM stapled BCL9 peptide.43 Furthermore, we
observed that the stereochemistry at cysteine seems to have an
inuence on the disruption behavior, with a superior inhibi-
tion constant observed for the D-enantiomer 9b compared to
that of the L-enantiomer 9a.
Since peptide stapling is known to improve cellular uptake
through endocytic vesicle trafficking46 and the BCL-9 and b-
catenin interaction takes place intracellularly in the cytoplasm
and the nucleus,45 we also tested the peptides' ability to
penetrate cells. By treating HeLa cells with 10 mM mixture of
10% uorescein labelled and 90% non-labelled peptides for
three hours, we observed that peptide 9b shows almost no
uptake, whereas the RCM stapled peptide 7 is taken up readily.
We attributed this to a recent observation from the Futaki lab,
in which they show the importance of net hydrophobicity for
the cellular uptake of stapled peptides.47 In order to increase
the hydrophobicity of our linkage, we synthesized peptide 13
with a more lipophilic O-benzyl-substituent at the phospho-
namidate. For this, the SPhR of the azido peptide 8b with
a benzyl phosphonite was carried out at slightly elevated
temperatures to ensure high conversions. The peptide was
only synthesized in the D-cysteine variant due to the afore-
mentioned improved disruption behavior towards the BCL-9
and b-catenin interaction. Isolated 13 showed comparable
helicity to the ethyl substituted 9b (Fig. 4d) and the benzyl-
substituent did not hamper the peptides' ability to disrupt
the PPI (Fig. 4e). In addition, we observed increased cellular
uptake of benzyl substituted 13, compared to 9b, which nicelyThis journal is © The Royal Society of Chemistry 2019
Fig. 4 (a) Stability of 9a at different pH values. Shown are mean and error from three independent measurements, monitored by UPLC-UV. (b)
UPLC-UV spectra of 9a upon incubation at pH 3.1 over several days. *P–N-bond cleavage is the only degradation product observed. (c)
Structures of differently cyclized BCL-9 peptides. Stated are isolated yields from the cyclization reaction. (d) CD-measurement of peptides. (e)
HTRF assay shows disruption of PPI by peptidic inhibitors. (f) Cellular uptake studies of 10 mM mixture of 10% carboxy-fluorescein (CF)-labelled
and 90% non-labelled peptides in HeLa cells. Confocal images with scale bar ¼ 20 mm. Depicted is the overlay of fluorescein-fluorescence and
Hoechst nucleus stain at different time points of laser (405/488 nm) irradiation.
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View Article Onlineillustrates the modularity of our method that allows a facile
exchange of the O-substituent of phosphonamidates to
modulate the functional properties of the peptide ligation
products.
In addition to the side-chain-stapled peptides, we further
expanded our novel cyclization method to a more general mac-
rocyclization technique for enhancing the cellular uptake prop-
erties of protein conjugates. Therefore, we aimed for the
cyclization of an R10 peptide, which is, like other arginine-rich
peptides, able to enhance the transduction of functional
proteins into living cells when covalently attached to the protein
cargo.48 We and others observed that the cellular transduction
behavior is signicantly improved for the cyclic version of cR10
when compared to its linear counterpart.22,49,50 As an alternative
to the previously applied cyclized R10-CPP 14, we synthesized
peptide 15 containing a cysteine and an azidohomoalanine
residue to replace the former lactam bridge aer our novelThis journal is © The Royal Society of Chemistry 2019cyclization technique. The linear unprotected peptide was reac-
ted with the crude diethylvinylphosphonite (route III) in dry
DMSO overnight to yield 48% of the in situmacrocyclized peptide
16 aer purication. For conjugation of 16 to a protein cargo,
the N-terminus of the peptide was capped with an
ethynylphosphonamidate-NHS building block 17 31 to yield 18
(Fig. 5a) for Cys-selective labeling reactions. Conjugation to eGFP
that carries a single addressable cysteine proceeded quantita-
tively according to MALDI-TOF-MS (Fig. 5b). Cellular uptake of
the protein was demonstrated by confocal uorescence imaging
aer incubation of HeLa-cells with 30 mM conjugate for one hour
at 37 C in HEPES buffer and was compared to that of the
standard lactam cyclized cR10-eGFP conjugate. Cytosolic and
nucleolar GFP uorescence was observed and both protein–
peptide-conjugates showed the same amount of transduced
cells, indicating the feasibility of using our novel cyclization
method as a macrocyclization technique (Fig. 5c).Chem. Sci., 2019, 10, 6322–6329 | 6327
Fig. 5 (a) Principle of the Staudinger induced peptide cyclization with R10 and subsequent attachment of a thiol reactive handle. (b) Conjugation
of cR10 to eGFP C70M S147C. Shown are MALDI-TOF-MS spectra before and after the reaction with 23. (c) Cellular uptake studies of 30 mM
eGFP-14 and eGFP-18 in HeLa cells. Confocal images with scale bar ¼ 10 mm.
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View Article OnlineConclusions
In summary, we introduce the SPhR with vinylphosphonites as
a versatile tool for the chemoselective cyclization of peptides.
Furthermore, we demonstrate that variation of the phosphonite's
O-substituent enables ne-tuning of the electrophilicity for
intermolecular protein and antibody labeling. Additionally, this
variation facilitates the incorporation of functional handles that
can modulate the properties of the reaction product as demon-
strated for the increased cellular uptake of phosphonamidate-
cyclized BCL9 peptides. Finally, the high yielding peptide cycli-
zation technique not only allows facile stapling of peptides but
furthermore also facilitates a general macrocyclization strategy as
shown for cCPPs. We believe that this tool will enable researchers
to develop both novel cysteine reactive probes for applications
where a narrow reactivity window is crucial and cyclic peptides
with enhanced pharmacological properties that can be manipu-
lated by phosphonamidate ester variation.Conflicts of interest
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